Levobupivacaine

Levobupivacaine works by reversibly blocking voltage‑gated sodium channels on neuronal membranes. This inhibition prevents the influx of sodium ions required for depolarisation, thereby stopping the initiation and propagation of nerve impulses and resulting in loss of sensation in the treated region.

The dose of Levobupivacaine is determined by the prescribing clinician based on the type of procedure, patient characteristics, and the desired duration of anesthesia. Healthcare professionals calculate the appropriate concentration and volume to achieve safe and effective nerve blockade.

Safety data for Levobupivacaine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Levobupivacaine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and offers a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Clinicians often prefer levobupivacaine when a safer safety profile is desired, especially in patients with cardiovascular concerns.

Levobupivacaine for injection should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze the product, and avoid exposing it to excessive heat or direct sunlight to maintain potency and sterility.

Levobupivacaine is administered by a qualified healthcare professional via intravenous, epidural, spinal, or peripheral nerve block techniques. The exact route, concentration, and volume depend on the clinical indication and the targeted anatomical site.

Serious risks include cardiovascular toxicity such as arrhythmias, cardiac arrest, and severe hypotension, as well as central nervous system toxicity manifesting as seizures or prolonged motor block. Immediate monitoring and resuscitation equipment should be available during administration.

Levobupivacaine should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, those with severe cardiac conduction disorders, or individuals with uncontrolled epilepsy. Caution is also advised for patients with significant hepatic impairment or those receiving interacting medications.